menu

NEWS

Ceres Receives $750K DOD Award

Ceres receives $750K award from US Department of Defense to adapt Nanotrap® Platform to Zika and emerging febrile illness pathogens from non-invasive sample types. Ceres Nanosciences, Inc. (Ceres) today announced the commencement of a development program, funded by the Defense Advanced Research Projects Agency (DARPA) of the US Department of Defense, to use Ceres’ Nanotrap® particle technology to commercialize sample processing tools for improved detection of Zika and other emerging pathogens from non-invasively collected urine and saliva specimens. During the 12-month performance of this program, Ceres will work in collaboration with George Mason University (GMU) to adapt the Nanotrap® platform...

READ MORE
Ceres Opens $9 Million Series A Round

Ceres Nanosciences opens $9 Million Series A round with $3 Million investment from GreyBird Ventures for the development of novel diagnostics powered by its Nanotrap® Platform. Ceres Nanosciences, Inc. today announced the completion of a $3MM Million Series A financing as part of a larger, $9MM Series A round. GreyBird Ventures, an early stage venture fund, with offices in Boston, is leading the round. GreyBird is committing up to $5.5MM over the next year, and is supporting Ceres in completing the round with additional investment from strategic industry partners. The Nanotrap technology was invented at George Mason University and developed...

READ MORE
Ceres Receives $980K DOD Award

Ceres receives $980K award from US Department of Defense to adapt Nanotrap® Platform to capture immune markers from non-invasive sample types. Ceres Nanosciences to collaborate with Tufts University and George Mason University to apply Nanotrap sample processing technology to capture panel of immune system markers for detection on the Quanterix Simoa platform Ceres Nanosciences, Inc. (Ceres) today announced the commencement of a development program, funded by the Defense Advanced Research Projects Agency (DAPRA) of the US Department of Defense, to use Ceres’ Nanotrap® particle technology to assess methods of detecting panels of immune function markers in non-invasive sample types. During...

READ MORE
Atlas5D announces $3 MM Series A from GreyBird Ventures

CAMBRIDGE, MA – Atlas5D, a leader in creating solutions to help people with reduced mobility live better and richer lives, announced a $3 million Series A venture capital investment from GreyBird Ventures, LLC, a venture firm that invests in early-stage companies developing products to accelerate the nascent trend of precision medicine. Atlas5D will use the infusion of capital to continue growing its team and expanding the business. Atlas5D develops ambient sensors to precisely quantify aspects of human motion and behavior, such as speed and strength. The populations served range from very young to very old, encompass a wide variety of...

READ MORE
Hummingbird Diagnostics & Saarland University Cooperate on Cancer Detection

Hummingbird Diagnostics & Saarland University cooperate on the early detection of cancer by liquid biopsy employing miRNA fingerprints Early detection as key for improved outcome The maybe best strategy in the daily fight against cancer – besides preventive actions such as anti-smoking campaigns – is the in-time detection of malignant tumors. There is an undisputed clinical need for minimally or non-invasive diagnostics that facilitate sensitive and specific discovery of cancers. The panel of possible approaches that is currently explored by research groups and companies worldwide includes different molecular diagnostic options, including protein patterns, gene expression profiles, epigenetics or metabolic marker...

READ MORE
Atlas5D announces collaboration with Biogen

Biogen is one of the world’s leading biotechnology companies, with a focus on developing therapies for neurodegenerative, hematologic and autoimmune disorders. Founded in 1978, Biogen’s work in biologics and small-molecule drug discovery has led to the world’s most extensive portfolio of multiple sclerosis (MS) therapies and innovative new treatments for hemophilia patients. Biogen seeks to enhance individualized treatment outcomes through emerging technology, clinical innovation, and continuous learning. Biogen’s work aims to capitalize on new and emerging technology to collect and better synthesize information in order to improve knowledge of disease impacts and therapies. Biogen became interested in Atlas5D’s technology, Echo5D,...

READ MORE
1 7 8 9
GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER